Coronavirus Disease 2019 (COVID-19) Real World Data Infrastructure: A Big-Data Resource for Study of the Impact of COVID-19 in Patient Populations With Immunocompromising Conditions DOI Creative Commons
James M. Crawford, Lynne Penberthy, Lígia A. Pinto

et al.

Open Forum Infectious Diseases, Journal Year: 2024, Volume and Issue: 12(1)

Published: Dec. 23, 2024

Abstract Background We developed a United States–based real-world data resource to better understand the continued impact of coronavirus disease 2019 (COVID-19) pandemic on immunocompromised patients, who are typically underrepresented in prospective studies and clinical trials. Methods The COVID-19 Real World Data infrastructure (CRWDi) was created by linking harmonizing de-identified HealthVerity medical pharmacy claims from 1 December 2018 31 2023, with severe acute respiratory syndrome 2 virologic serologic laboratory major commercial laboratories Northwell Health; vaccination data; and, for patients cancer, 2010 2021 National Cancer Institute Surveillance, Epidemiology, End Results registry data. CRWDi contains 4 cohorts: cancer; rheumatic diseases receiving pharmacotherapy; noncancer solid organ hematopoietic stem cell transplant recipients; people general population including adults pediatric patients. project successfully linked harmonized longitudinal, 5.2 million unique using privacy-preserving record lineage techniques. system early 2024 rapidly deployed, enabling longitudinal analysis patient healthcare over full geography delivery settings exploration novel questions populations at high risk adverse outcomes. Conclusions successful development enables researchers address unanswered that have arisen during pandemic. By making broadly freely available academic researchers, this represents an important complement existing consortia trials emerged crisis is readily reproducible future purposing.

Language: Английский

Progress and prospects of mRNA-based drugs in pre-clinical and clinical applications DOI Creative Commons
Yingying Shi,

Miaoyuan Shi,

Yì Wáng

et al.

Signal Transduction and Targeted Therapy, Journal Year: 2024, Volume and Issue: 9(1)

Published: Nov. 14, 2024

Abstract In the last decade, messenger ribonucleic acid (mRNA)-based drugs have gained great interest in both immunotherapy and non-immunogenic applications. This surge can be largely attributed to demonstration of distinct advantages offered by various mRNA molecules, alongside rapid advancements nucleic delivery systems. It is noteworthy that immunogenicity presents a double-edged sword. context immunotherapy, extra supplementation adjuvant generally required for induction robust immune responses. Conversely, non-immunotherapeutic scenarios, activation unwanted considering host tolerability high expression demand mRNA-encoded functional proteins. Herein, mainly focused on linear non-replicating mRNA, we overview preclinical clinical progress prospects medicines encompassing vaccines other therapeutics. We also highlight importance focusing host-specific variations, including age, gender, pathological condition, concurrent medication individual patient, maximized efficacy safety upon administration. Furthermore, deliberate potential challenges may encounter realm disease treatment, current endeavors improvement, as well application future advancements. Overall, this review aims present comprehensive understanding mRNA-based therapies while illuminating prospective development drugs.

Language: Английский

Citations

11
Navigating Coronavirus Disease 2019 in Immunocompromised Populations DOI
Majd Alsoubani, Jennifer Chow

Infectious Disease Clinics of North America, Journal Year: 2025, Volume and Issue: unknown

Published: March 1, 2025

Language: Английский

Citations

0
The equitable aging in health conceptual framework: international interventions infusing power and justice to address social isolation and loneliness among older adults DOI Creative Commons
Angela Perone,

Leixuri Urrutia-Pujana,

Leyi Zhou

et al.

Frontiers in Public Health, Journal Year: 2025, Volume and Issue: 13

Published: March 10, 2025

Introduction Social isolation and loneliness among older adults have garnered significant international attention, particularly as structures services evolved during a global pandemic. A growing body of research underscores disparities in social intersecting (e.g., race, ethnicity, age, gender, sexual orientation, disability) physical rural/urban) locations. While empirical data about these trends has increased, conceptual theoretical frameworks are underdeveloped loneliness, especially from perspective. This article presents novel equitable aging framework to help contextualize, understand, explain how power influences adults. Equitable health builds on principles critical gerontology, public concepts political determinants health, human rights, intersectionality present new for researchers, policymakers, practitioners. centers five domains (intrapersonal, interpersonal, disciplinary, structural, cultural) components (or hub) that drive six (economic stability, education access quality, care neighborhood built environment, community context, laws politics). The sixth determinant (laws policies) incorporates rights (economic, social, cultural, civil, rights). When justice is infused power, can produce outcomes. Aging Health Framework tool understand ultimately achieve opportunities connections Discussion To illustrate the utility this framework, case studies interventions China, Taiwan, Spain, Sweden, Mexico, United States employ address diverse communities These propose services, programs, policies infuse different paradigms various ways build support

Language: Английский

Citations

0
Risk of Severe COVID-19 in Four Immunocompromised Populations: A French Expert Perspective DOI Creative Commons
Paul Loubet, Iliès Benotmane, Slim Fourati

et al.

Infectious Diseases and Therapy, Journal Year: 2025, Volume and Issue: unknown

Published: March 18, 2025

Immunocompromised patients are disproportionately impacted by severe disease, hospitalization, and mortality associated with coronavirus disease 2019 (COVID-19). To optimize the management of these in clinical practice, we convened an expert panel to review current evidence on acute respiratory syndrome 2 (SARS-CoV-2) vaccine responses COVID-19 immunocompromised populations. We identified four main groups—solid organ transplant recipients, receiving allogeneic hematopoietic stem cell transplantation or chimeric antigen receptor (CAR) T therapy, treated for hematologic malignancies, inflammatory diseases—who mount suboptimal humoral SARS-CoV-2 vaccination at increased risk COVID-19-related outcomes. A wide range factors were reduced and/or poor outcomes, most commonly older age, comorbidities, type number immunosuppressive therapies. believe that early identification close monitoring at-risk patients, plus regular booster vaccinations, prophylactic monoclonal antibody non-pharmacologic prevention measures, prompt antiviral treatment, other mitigation strategies, critical protect against infection COVID-19. Although people will fully recover from COVID-19, who less able fight more likely be hospitalized die improve treatment people, 10 experts France met discuss latest medical research this area. The focused groups people: (1) transplants; (2) transplants therapy; (3) being blood cancers; (4) diseases (such as rheumatoid arthritis). These protected after develop forms pre-existing conditions diabetes, obesity, heart, lung, kidney disease), immunosuppressants. agreed it is important quickly identify clinic, so they can receive vaccines every 6 months. For unable build up their immunity vaccination, treatments also used prevent infection. In recommend using therapies nirmatrelvir/ritonavir remdesivir) becoming severe. addition measures mask wearing social distancing), strategies help

Language: Английский

Citations

0
Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art” DOI

Marcial Delgado‐Fernández,

Juan Diego Ruíz-Mesa,

Almudena Rojas-González

et al.

Enfermedades Infecciosas y Microbiología Clínica, Journal Year: 2025, Volume and Issue: unknown

Published: April 1, 2025

Language: Английский

Citations

0
The DESTINIES Study: an online Delphi study to build international consensus on the medical conditions and procedures that confer immunosuppression and their respective COVID-19 risk profiles DOI Creative Commons
Meredith Leston, José M. Ordóñez‐Mena, Mark Joy

et al.

EClinicalMedicine, Journal Year: 2025, Volume and Issue: 83, P. 103239 - 103239

Published: May 1, 2025

Language: Английский

Citations

0
Fresh frozen plasma for neutralizing SARS-CoV-2: “An exploratory cross-sectional study and review of the state of the art” DOI

Marcial Delgado‐Fernández,

Juan Diego Ruíz-Mesa,

Almudena Rojas-González

et al.

Enfermedades infecciosas y microbiologia clinica (English ed ), Journal Year: 2025, Volume and Issue: 43(5), P. 282 - 290

Published: May 1, 2025

Language: Английский

Citations

0
COVID-19 mortality amongst the immunosuppresed DOI
Víctor Moreno‐Torres, María Martínez‐Urbistondo, Jorge Calderón‐Parra

et al.

Journal of Infection, Journal Year: 2024, Volume and Issue: 88(4), P. 106137 - 106137

Published: March 11, 2024

Language: Английский

Citations

2
Management of patients with neurological diseases considering post‐pandemic coronavirus disease 2019 (COVID‐19) related risks and dangers — An updated European Academy of Neurology consensus statement DOI Creative Commons
Saša R. Filipović, Şerefnur Öztürk, Dániel Bereczki

et al.

European Journal of Neurology, Journal Year: 2024, Volume and Issue: 31(10)

Published: Aug. 1, 2024

In October 2020, the European Academy of Neurology (EAN) consensus statement for management patients with neurological diseases during coronavirus disease 2019 (COVID-19) pandemic was published. Due to important changes and developments that have happened since then, need has arisen critically reassess original recommendations address new challenges.

Language: Английский

Citations

2
An eDElphi STudy to defINe and risk-stratify ImmunosupprESsion: Protocol for the DESTINIES Study (Preprint) DOI Creative Commons
Meredith Leston,

José Ordóñez-Mena,

Mark Joy

et al.

JMIR Research Protocols, Journal Year: 2024, Volume and Issue: 13, P. e56271 - e56271

Published: April 29, 2024

Globally, there are marked inconsistencies in how immunosuppression is characterized and subdivided into clinical risk groups. This detrimental to the precision comparability of disease surveillance efforts-which has negative implications for care those who immunosuppressed their health outcomes. was particularly apparent during COVID-19 pandemic; despite collective motivation protect these patients, conflicting definitions created international rifts were monitored managed this period. We propose that consensus be built around conditions lead gradations severity concerning COVID-19. Such information can then formalized a digital phenotype enhance provide much-needed intelligence on risk-prioritizing patients.

Language: Английский

Citations

1